Search

Your search keyword '"Christopher Pocock"' showing total 4 results
Start Over Author "Christopher Pocock" Journal hematological oncology
4 results on '"Christopher Pocock"'

1. BRIEF CO-ADMINISTRATION OF IDELALISIB MAY IMPROVE THE LONG-TERM EFFICACY OF FRONTLINE CHEMOIMMUNOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKAEMIA: 3-YEAR FOLLOW-UP FROM THE RIALTO TRIAL

Author

M. Aldouri, Ke Lin, C. Murphy, Christopher P. Fox, Geetha Menon, Shankara Paneesha, Melanie Oates, Sarah E. Coupland, Peter Hillmen, Nagesh Kalakonda, Deborah Turner, S. Jenkins, F. Wandroo, P. Cervi, Anna Schuh, Saad M. B. Rassam, Andrew S Duncombe, Michael R. Hamblin, Silvia Cicconi, Christopher Pocock, C. Knechtli, and Andrew R. Pettitt

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Lymphocytic leukaemia, business.industry, Hematology, General Medicine, Chemoimmunotherapy, Internal medicine, medicine, business, Idelalisib, Co administration
Published
2019

2. IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN a SUBSET OF PATIENTS IN THE RANDOMISED GALLIUM TRIAL WITH PREVIOUSLY UNTREATED MARGINAL ZONE LYMPHOMA (MZL)

Author

Alessandra Tedeschi, Kaspar Rufibach, Marek Trněný, Günter Fingerle-Rowson, Ann Janssens, Eva Hoster, Helen McCarthy, András Rosta, Harald Zeuner, P. Schmidt, Michael Herold, Wolfgang Hiddemann, Christopher Pocock, Robert Marcus, and A. Burciu

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, business.industry, Marginal zone lymphoma, chemistry.chemical_element, Hematology, General Medicine, 03 medical and health sciences, chemistry.chemical_compound, 030104 developmental biology, 0302 clinical medicine, chemistry, Obinutuzumab, 030220 oncology & carcinogenesis, Internal medicine, Immunology, medicine, Rituximab, Gallium, business, medicine.drug
Published
2017

3. EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: PRELIMINARY RESULTS FROM THE NCRI RIALTO TRIAL

Author

Andrew R. Pettitt, Deborah Turner, Anna Schuh, Melanie Oates, Saad M. B. Rassam, Christopher Pocock, Christopher P. Fox, Nagesh Kalakonda, Fotis Polydoros, Peter Hillmen, Geetha Menon, S. Jenkins, Sarah E. Coupland, P. Cervi, C. Knechtli, Ke Lin, Michael R. Hamblin, Andrew S Duncombe, M. Jenner, Matthew Bickerstaff, Shankara Paneesha, M. Aldouri, and F. Wandroo

Subjects
Bendamustine, Oncology, Cancer Research, medicine.medical_specialty, Chlorambucil, business.industry, Hematology, General Medicine, Ofatumumab, chemistry.chemical_compound, chemistry, Internal medicine, medicine, Idelalisib, business, medicine.drug
Published
2017

4. DIFFERENTIAL EFFICACY OF BORTEZOMIB IN SUBTYPES OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBL): a PROSPECTIVE RANDOMISED STUDY STRATIFIED BY TRANSCRIPTOME PROFILING: REMODL-B

Author

Urban Novak, David R. Westhead, Thomas Cummin, Michael A. Bentley, Christopher Pocock, Reuben Tooze, Tom Maishman, S. Barrans, Michael Wang, Debbie Hamid, Matthew A. Care, Alexandra Clipson, Paul Fields, Andrew McMillan, Chulin Sha, Peter Johnson, Andrew Jack, Andrew Davies, Shamim Kazmi-Stokes, Graham P. Collins, Anton Kruger, Joshua Caddy, Gareth Griffiths, Ming-Qing Du, C. Burton, and Christoph Mamot

Subjects
Cancer Research, Pathology, medicine.medical_specialty, Bortezomib, Germinal center, Hematology, General Medicine, Biology, medicine.disease, Phenotype, 03 medical and health sciences, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Gene expression, medicine, Transcriptome profiling, Diffuse large B-cell lymphoma, 030215 immunology, medicine.drug
Abstract

DLBL subtypes identified by patterns of gene expression correspond to germinal center (GCB) or activated (ABC) B‐cells like. The latter demonstrate dysregulation of the NF‐KB pathway. Outcomes of treatment with R‐CHOP are inferior for ABC DLBL in retrospective series. This study investigated whether adding bortezomib (B), a putative NF‐KB inhibitor, can reverse this phenotype.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results